Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Whitehawk Therapeutics Inc (WHWK)
USD3.87
+0.06 (+1.57%)
US NASDAQ Healthcare Biotechnology
Address
17383 Sunset Blvd, Suite A250 90272
Pacific Palisades, CA, US
Pacific Palisades, CA, US
CEO
David J. Lennon
Website
ir.whitehawktx.com
IPO
2017-08-01
CIK 1422142 ISIN US00032Q1040
Also trades on
NASDAQ Capital Market · AADI (USD)
NASDAQ Global Market · WHWK (USD)
Description
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.87
+0.06 (+1.57%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
422.0K
Beta
0.77
Float Shares
18.15M
Free Float %
36.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.28% | -8.21% | +12.09% | +26.25% | +70.40% | +57.02% | +127.54% | -45.32% | -78.16% | -95.78% | -95.78% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3.87
Low
7.00
+80.9%
Consensus
7.00
+80.9%
Median
7.00
+80.9%
High
7.00
+80.9%
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
7.00
+80.9%
|
| Last Quarter | 1 |
7.00
+80.9%
|
| Last Year | 2 |
6.50
+68.0%
|
| All Time | 2 |
6.50
+68.0%
|
Quality scores
Altman Z-Score
4.52
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-72.5% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+86.0% ★ Q1'26: -117.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,574.1%
-
EBIT margin Biotechnology: +0.0%-1,601.1%
-
ROIC Biotechnology: -16.1%— Q1'26: +1,369.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+129.0% Q1'26: +155.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
20.18M
est.
|
14.58M
est: 15.00M (-2.8%)
|
1.12M
est: 75.0K (+1,393.3%)
|
15.22M
est: 14.24M (+6.9%)
|
24.35M
est: 24.13M (+0.9%)
|
25.98M
est: 25.89M (+0.4%)
|
7.15M
est: 7.13M (+0.2%)
|
8.83M
8.83M – 8.83M
+23.8% YoY
|
10.91M
10.91M – 10.91M
+23.6% YoY
|
13.48M
13.48M – 13.48M
+23.6% YoY
|
16.65M
16.65M – 16.65M
+23.6% YoY
|
20.58M
20.58M – 20.58M
+23.6% YoY
|
| EBITDA |
-16.85M
est.
|
-2.54M
est: -12.52M (+79.7%)
|
-36.96M
est: -62.6K (-58,922.9%)
|
-58.80M
est: -11.89M (-394.7%)
|
-71.76M
est: -20.14M (-256.3%)
|
-64.63M
est: -25.89M (-149.6%)
|
-114.40M
est: -7.13M (-1,503.6%)
|
-8.83M
-8.83M – -8.83M
-23.8% YoY
|
-10.91M
-10.91M – -10.91M
-23.6% YoY
|
-13.48M
-13.48M – -13.48M
-23.6% YoY
|
-16.65M
-16.65M – -16.65M
-23.6% YoY
|
-20.58M
-20.58M – -20.58M
-23.6% YoY
|
| EBIT |
-16.85M
est.
|
-2.55M
est: -12.52M (+79.6%)
|
-37.06M
est: -62.6K (-59,082.1%)
|
-58.96M
est: -11.89M (-395.9%)
|
-71.93M
est: -20.15M (-257.0%)
|
-64.82M
est: -25.89M (-150.4%)
|
-114.40M
est: -7.13M (-1,503.6%)
|
-8.83M
-8.83M – -8.83M
-23.8% YoY
|
-10.91M
-10.91M – -10.91M
-23.6% YoY
|
-13.48M
-13.48M – -13.48M
-23.6% YoY
|
-16.65M
-16.65M – -16.65M
-23.6% YoY
|
-20.58M
-20.58M – -20.58M
-23.6% YoY
|
| Net Income |
-128.73M
est.
|
-3.48M
est: -57.11M (+93.9%)
|
-110.09M
est: -185.43M (+40.6%)
|
-60.51M
est: -77.85M (+22.3%)
|
-65.77M
est: -67.36M (+2.4%)
|
-63.69M
est: -126.56M (+49.7%)
|
-20.60M
est: -1.61M (-1,180.0%)
|
-98.24M
-101.94M – -67.57M
-6,005.1% YoY
|
-82.15M
-98.59M – -65.72M
+16.4% YoY
|
-73.04M
-111.15M – -34.93M
+11.1% YoY
|
-69.62M
-69.62M – -69.62M
+4.7% YoY
|
-63.43M
-63.43M – -63.43M
+8.9% YoY
|
| SGA |
91.03M
est.
|
2.12M
est: 67.67M (-96.9%)
|
18.51M
est: 338.4K (+5,370.9%)
|
40.18M
est: 64.23M (-37.5%)
|
44.55M
est: 108.86M (-59.1%)
|
36.75M
est: 137.66M (-73.3%)
|
29.82M
est: 37.93M (-21.4%)
|
46.94M
46.94M – 46.94M
+23.8% YoY
|
58.00M
58.00M – 58.00M
+23.6% YoY
|
71.67M
71.67M – 71.67M
+23.6% YoY
|
88.55M
88.55M – 88.55M
+23.6% YoY
|
109.42M
109.42M – 109.42M
+23.6% YoY
|
| EPS |
-4.76
est.
|
-0.21
est: -2.11 (+90.1%)
|
-12.41
est: -6.86 (-80.9%)
|
-2.69
est: -2.88 (+6.6%)
|
-2.44
est: -2.49 (+2.1%)
|
-2.36
est: -2.05 (-15.4%)
|
-0.33
est: -0.03 (-1,169.2%)
|
-1.35
-1.65 – -1.09
-5,076.9% YoY
|
-1.33
-1.59 – -1.06
+1.4% YoY
|
-1.17
-1.80 – -0.56
+11.9% YoY
|
-1.13
-1.13 – -1.13
+3.8% YoY
|
-1.03
-1.03 – -1.03
+8.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-99.84M
OE per share TTM
-2.05
Owner's Yield
-36.32%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
18.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 37 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.42% | 92.3K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.03% | 439.0K | 0.60% |
| 3 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.02% | 197.6K | 0.20% |
| 4 | iShares Russell 2000 Value ETF IWN | 0.01% | 1.11M | 0.24% |
| 5 | Avantis U.S. Small Cap Equity ETF AVSC | 0.01% | 202.8K | 0.25% |
| 6 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.00% | 129.9K | 0.30% |
| 7 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 13.2K | 0.25% |
| 8 | Global X - Russell 2000 ETF RSSL | 0.00% | 60.2K | 0.08% |
| 9 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 2.0K | 0.39% |
| 10 | iShares Russell 2000 ETF IWM | 0.00% | 2.97M | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.57
Neutral
Ratio by volume
1.54
Bullish
Buys
8
Sells
14
Shares acquired
3.56M
Shares disposed
2.31M
Cash buys
—
Cash sales
11.00
Net activity
+1,251,550
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Giacobello Scott M. | Officer | S-Sale | D | Common Stock | 141,600 | 4.13 | 584.8K | 295,224 | D | ↗ |
| 2026-04-15 | Giacobello Scott M. | Officer | S-Sale | D | Common Stock | 77,000 | 3.86 | 297.2K | 436,824 | D | ↗ |
| 2026-04-14 | BALL BRYAN | Officer | S-Sale | D | Common Stock | 92,460 | 3.64 | 336.6K | 397,106 | D | ↗ |
| 2026-04-13 | BALL BRYAN | Officer | S-Sale | D | Common Stock | 26,389 | 3.46 | 91.3K | 489,566 | D | ↗ |
| 2026-04-10 | BALL BRYAN | Officer | S-Sale | D | Common Stock | 6,596 | 3.43 | 22.6K | 515,955 | D | ↗ |
| 2026-04-09 | Lennon David James | Director / Officer | S-Sale | D | Common Stock | 14,500 | 3.38 | 49.0K | 518,622 | D | ↗ |
| 2026-04-09 | BALL BRYAN | Officer | S-Sale | D | Common Stock | 50,000 | 3.57 | 178.5K | 522,551 | D | ↗ |
| 2026-04-08 | Lennon David James | Director / Officer | S-Sale | D | Common Stock | 63,945 | 3.40 | 217.4K | 533,122 | D | ↗ |
| 2026-04-07 | Lennon David James | Director / Officer | S-Sale | D | Common Stock | 94,087 | 3.43 | 322.7K | 597,067 | D | ↗ |
| 2026-04-06 | Lennon David James | Director / Officer | S-Sale | D | Common Stock | 102,395 | 3.51 | 359.4K | 691,154 | D | ↗ |
| 2026-04-02 | Lennon David James | Director / Officer | S-Sale | D | Common Stock | 26,858 | 3.48 | 93.5K | 793,549 | D | ↗ |
| 2026-04-01 | Lennon David James | Director / Officer | M-Exempt | D | Restricted Stock Units | 775,828 | 0.00 | — | 0 | D | ↗ |
| 2026-04-01 | Giacobello Scott M. | Officer | M-Exempt | A | Common Stock | 473,902 | 0.00 | — | 502,002 | D | ↗ |
| 2026-04-01 | Dugan Margaret | Officer | A-Award | A | Stock Option (right to buy) | 283,157 | 3.54 | 1.00M | 283,157 | D | ↗ |
| 2026-04-01 | Dornan David | Officer | A-Award | A | Stock Option (right to buy) | 282,340 | 3.54 | 999.5K | 282,340 | D | ↗ |
| 2026-04-01 | BALL BRYAN | Officer | M-Exempt | A | Common Stock | 366,532 | 0.00 | — | 572,551 | D | ↗ |
| 2026-03-02 | Lennon David James | Director / Officer | S-Sale | D | Common Stock | 5,100 | 3.31 | 16.9K | 44,579 | D | ↗ |
| 2026-03-02 | Giacobello Scott M. | Officer | S-Sale | D | Common Stock | 2,594 | 3.31 | 8.6K | 28,100 | D | ↗ |
| 2026-03-02 | BALL BRYAN | Officer | S-Sale | D | Common Stock | 1,834 | 3.31 | 6.1K | 206,019 | D | ↗ |
| 2026-03-01 | Lennon David James | Director / Officer | M-Exempt | D | Restricted Stock Units | 16,250 | 0.00 | — | 32,500 | D | ↗ |
| 2026-03-01 | Giacobello Scott M. | Officer | M-Exempt | A | Common Stock | 6,750 | 0.00 | — | 30,694 | D | ↗ |
| 2026-03-01 | BALL BRYAN | Officer | M-Exempt | A | Common Stock | 5,000 | 0.00 | — | 207,853 | D | ↗ |
| 2025-12-01 | Dugan Margaret | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-17 | Zhao Baiteng | Director | A-Award | A | Stock Option (right to buy) | 40,006 | 2.04 | 81.6K | 40,006 | D | ↗ |
| 2025-06-12 | Reeve Emma | Director | A-Award | A | Stock Option (right to buy) | 40,006 | 2.04 | 81.6K | 40,006 | D | ↗ |
| 2025-06-12 | Maroun Richard E | Director | A-Award | A | Stock Option (right to buy) | 40,006 | 2.04 | 81.6K | 40,006 | D | ↗ |
| 2025-06-12 | Hirmand Mohammad | Director | A-Award | A | Stock Option (right to buy) | 40,006 | 2.04 | 81.6K | 40,006 | D | ↗ |
| 2025-06-12 | Desai Neil | Director | A-Award | A | Stock Option (right to buy) | 40,006 | 2.04 | 81.6K | 40,006 | D | ↗ |
| 2025-06-12 | Dalal Anupam | Director | A-Award | A | Stock Option (right to buy) | 40,006 | 2.04 | 81.6K | 40,006 | D | ↗ |
| 2025-06-12 | Castelein Caley | Director | A-Award | A | Stock Option (right to buy) | 40,006 | 2.04 | 81.6K | 40,006 | D | ↗ |
| 2025-06-12 | Aghazadeh Behzad | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 40,006 | 2.04 | 81.6K | 40,006 | D | ↗ |
| 2025-04-01 | Lennon David James | Director / Officer | A-Award | A | Restricted Stock Units | 775,828 | 0.00 | — | 775,828 | D | ↗ |
| 2025-04-01 | Giacobello Scott M. | Officer | A-Award | A | Restricted Stock Units | 473,902 | 0.00 | — | 473,902 | D | ↗ |
| 2025-04-01 | BALL BRYAN | Officer | A-Award | A | Stock Option (right to buy) | 366,532 | 1.70 | 623.1K | 366,532 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-28.6K
Shares Outstanding
49.45M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David J. Lennon | President, Chief Executive Officer & Director | 1M | — |
| Scott Giacobello | Chief Financial Officer, Treasurer, Investor Relations & Corporate Communications | 721.6K | male |
| Bryan Ball | Chief Technical Operations Officer | 687.5K | male |
| Neil Desai | Founder & Director | 40.0K | — |
| Margaret Han Dugan | Chief Medical Officer | — | — |
| David Dornan | Chief Scientific Officer | — | — |
| Stephen Rodin | Senior Vice President of Legal & General Counsel | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WHWK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
